In the global arena of biomedicine, Guangzhou's innovative drug companies are rewriting the rules with "hard‑core technology.

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

IDEAYA Biosciences', a developmental biotech, valuation declined over 50% since mid-2024. Check out why I'm coming away with ...

Explore how innovation, R&D, and policy reforms are reshaping China’s pharmaceutical sector amid rising healthcare demand and demographic shifts.

Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

"China's biotechnology sector thrives on a dual engine — Beijing's constellation of famous medical universities training ...

Under the terms of the settlement, Pacira has agreed to provide Fresenius with a license to its patents required to ...

HIES and HRC had announced partnering to optimise compressed air system efficiency for HRC’s operations. The reinforced ...

Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) leaped 15% following the announcement of a settlement in U.S. patent litigation concerning its flagship product, EXPAREL. The agreement effectively ...

BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui ...